PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P Biopsy tissue–based ...

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL ...

Prostate cancer is the most common cancer affecting men in Namibia, with an alarmingly high rate of 63.8 cases per 100 000 men. In Sub-Saharan Africa, this number is predicted to at least triple by ...

The Urology Care Foundation and the Prostate Cancer Foundation have created a new educational guide on genetic tests to guide ...

TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials ASCO Guidelines provide recommendations with comprehensive ...

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...

Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that ...

Decision making is evidence based and must be shielded from lobbying The NHS draft recommendation against routine prostate ...

If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...